Literature DB >> 29267937

Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies.

E L Korn1, B Freidlin2.   

Abstract

The goal of a non-inferiority randomized trial is to demonstrate that an experimental treatment is not unacceptably worse than a standard treatment. The experimental treatment is known to have less toxicity or other quality-of-life benefits when compared with the standard treatment, so that a small decrement in efficacy would be acceptable. Interim monitoring of randomized trials is used to stop trials early if the conclusions of the trial become definitive early. In the context of a non-inferiority trial, of special interest is stopping a trial early when the experimental treatment is inferior to the standard treatment. Methods for performing interim monitoring of non-inferiority trials are reviewed for their ability to minimize patient exposure to inferior experimental treatments. Examples of trials from the literature are discussed along with a computer simulation of a simple non-inferiority monitoring rule. Interim monitoring for non-inferiority trials is shown to substantially reduce the exposure of patients to inferior therapies when, in fact, the experimental treatment is inferior to the standard treatment. Interim monitoring rules typically used in superiority trials may be sub-optimal for non-inferiority trials, and may unnecessarily expose patients to inferior therapies. Examples of trials with inferior experimental arms and trials with sub-optimal monitoring rules are given. Appropriate interim monitoring of non-inferiority trials can reduce the exposure of patients to inferior therapies when the experimental treatment is inferior to the standard treatment.

Entities:  

Mesh:

Year:  2018        PMID: 29267937      PMCID: PMC6248434          DOI: 10.1093/annonc/mdx788

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  3 in total

1.  Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Authors:  Maura L Gillison; Andy M Trotti; Jonathan Harris; Avraham Eisbruch; Paul M Harari; David J Adelstein; Richard C K Jordan; Weiqiang Zhao; Erich M Sturgis; Barbara Burtness; John A Ridge; Jolie Ringash; James Galvin; Min Yao; Shlomo A Koyfman; Dukagjin M Blakaj; Mohammed A Razaq; A Dimitrios Colevas; Jonathan J Beitler; Christopher U Jones; Neal E Dunlap; Samantha A Seaward; Sharon Spencer; Thomas J Galloway; Jack Phan; James J Dignam; Quynh Thu Le
Journal:  Lancet       Date:  2018-11-15       Impact factor: 79.321

2.  Futility stopping in non-inferiority trials.

Authors:  Zheng Su; Mark Stuntz
Journal:  Contemp Clin Trials Commun       Date:  2018-12-04

3.  Estimated oxygen extraction versus dynamic parameters of fluid-responsiveness for perioperative hemodynamic optimization of patients undergoing non-cardiac surgery: a non-inferiority randomized controlled trial.

Authors:  Andrea Carsetti; Mirco Amici; Tonino Bernacconi; Paolo Brancaleoni; Elisabetta Cerutti; Marco Chiarello; Diego Cingolani; Luisanna Cola; Daniela Corsi; Giorgio Forlini; Marina Giampieri; Salvatore Iuorio; Tiziana Principi; Giuseppe Tappatà; Michele Tempesta; Erica Adrario; Abele Donati
Journal:  BMC Anesthesiol       Date:  2020-04-18       Impact factor: 2.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.